{"id":92405,"date":"2024-02-01T11:24:45","date_gmt":"2024-02-01T10:24:45","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/"},"modified":"2025-10-13T15:12:06","modified_gmt":"2025-10-13T13:12:06","slug":"stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/","title":{"rendered":"Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics"},"content":{"rendered":"<p><strong>La empresa biotecnol\u00f3gica en fase cl\u00ednica <a href=\"https:\/\/www.pcb.ub.edu\/es\/empresa\/onechain-immunotherapeutics-s-l\/\" target=\"_blank\" rel=\"noopener\">OneChain Immunotherapeutics (OCI)<\/a>, ubicada en el Parque Cient\u00edfico de Barcelona y centrada en el desarrollo de terapias CAR T para el tratamiento de enfermedades oncol\u00f3gicas, ha anunciado el nombramiento del doctor Stefanos Theoharis como nuevo director general de la compa\u00f1\u00eda. Suceder\u00e1 en el cargo a Jorge Alemany, que ha ocupado esta posici\u00f3n desde la creaci\u00f3n de la empresa en junio de 2020, y ahora se retira.<\/strong><\/p>\n<p><strong>Stefanos Theoharis<\/strong> aporta a <a href=\"https:\/\/www.onechaintx.com\/\" target=\"_blank\" rel=\"noopener\">OCI<\/a> m\u00e1s de veinte a\u00f1os de experiencia en el campo de la terapia celular y g\u00e9nica, el desarrollo empresarial, la gesti\u00f3n de programas y la fabricaci\u00f3n. Su carrera incluye puestos clave como el de director de Negocios en Bone Therapeutics, una empresa con sede en B\u00e9lgica especializada en terapias celulares para trastornos ortop\u00e9dicos, vicepresidente senior en Cell Medica y director de negocios en Apceth Biopharma GmbH. Tambi\u00e9n ocup\u00f3 cargos como director de desarrollo de negocio en la empresa de f\u00e1rmacos de ARN antisentido Isarna, y director de desarrollo de negocio en Roche, centrado en actividades de asociaci\u00f3n para tecnolog\u00edas emergentes. Antes de esto, tambi\u00e9n trabaj\u00f3 en Lazard, el banco de inversi\u00f3n global, asesorando a varias empresas de ciencias de la vida en fusiones y adquisiciones y operaciones de financiaci\u00f3n. Se doctor\u00f3 en el Imperial College de Londres en 2004, en terapia g\u00e9nica e inmunolog\u00eda.<\/p>\n<p>\u00abEstoy emocionado de aportar mi perspectiva al excepcional equipo de cient\u00edficos y l\u00edderes empresariales que forman esta empresa\u00bb, explica <strong>Theoharis<\/strong>. \u00abLo que realmente me entusiasma de este puesto es que la empresa es lo suficientemente joven como para tener un importante potencial de crecimiento y desarrollo y, al mismo tiempo, lo suficientemente madura como para haber establecido una s\u00f3lida trayectoria y participar en proyectos apasionantes\u00bb, a\u00f1ade.<\/p>\n<p>Bajo la direcci\u00f3n del anterior CEO, el <strong>Dr. Jorge Alemany<\/strong>, OCI ha alcanzado r\u00e1pidamente hitos significativos en el campo de las terapias CAR T. Fundada en 2020 por el <a href=\"https:\/\/www.carrerasresearch.org\/ca\/institut\/benvinguda\" target=\"_blank\" rel=\"noopener\">Institut de Investigaci\u00f3n contra la Leucemia Josep Carreras<\/a>, la Instituci\u00f3n Catalana de Investigaci\u00f3n y Estudios Avanzados (<a href=\"https:\/\/www.icrea.cat\/\" target=\"_blank\" rel=\"noopener\">ICREA<\/a>) y el <a href=\"https:\/\/www.carrerasresearch.org\/ca\/directori\/pablo-menendez-118\" target=\"_blank\" rel=\"noopener\"><strong>Dr. Pablo Men\u00e9ndez<\/strong><\/a>, la compa\u00f1\u00eda alcanz\u00f3 la fase cl\u00ednica en menos de tres a\u00f1os y ha reforzado su pipeline con una nueva plataforma alog\u00e9nica, un segundo programa contra tumores hematol\u00f3gicos y otro contra tumores s\u00f3lidos. Adem\u00e1s, OCI cerr\u00f3 con \u00e9xito una ronda de financiaci\u00f3n pre-serie A hace apenas siete meses, recaudando 15 millones de euros en total, entre financiaci\u00f3n dilutiva y no dilutiva.<\/p>\n<p><strong>Theoharis<\/strong> se incorpora a OCI en un momento crucial, con el objetivo de dirigir la empresa hacia una nueva fase de desarrollo de sus terapias. El nuevo director general tiene previsto centrarse en aspectos como la fabricaci\u00f3n, el reclutamiento de pacientes y el acceso al mercado, y subraya la importancia de establecer asociaciones estrat\u00e9gicas para hacer avanzar los proyectos de OCI a la siguiente fase. \u00abUna parte esencial de mi funci\u00f3n ser\u00e1 aportar a la empresa la reputaci\u00f3n internacional y la red de contactos que he construido durante mis 20 a\u00f1os de trabajo en la industria farmac\u00e9utica. Me entusiasma contribuir a esta nueva fase de la empresa, en la que pretendemos crecer no s\u00f3lo en nuestra cartera de productos, sino tambi\u00e9n en el desarrollo interno de nuestro equipo\u00bb, afirma.<\/p>\n<p>En este contexto de cambio y oportunidad, los miembros de la junta directiva de OCI tambi\u00e9n han expresado su entusiasmo por la llegada del nuevo CEO. \u00abStefanos posee una combinaci\u00f3n excepcional de conocimientos cient\u00edficos y experiencia empresarial, desarrollada a trav\u00e9s de puestos clave en empresas biotecnol\u00f3gicas y farmac\u00e9uticas. Su profundo conocimiento de las terapias celulares y g\u00e9nicas, las terapias CAR y la inmuno-oncolog\u00eda encaja a la perfecci\u00f3n con el potencial innovador de la empresa. Con Stefanos al tim\u00f3n, OneChain est\u00e1 bien preparada para embarcarse en su pr\u00f3xima fase de crecimiento\u00bb, comenta <strong>Laura Rodr\u00edguez<\/strong>, principal de Invivo y miembro del Consejo de OneChain.<\/p>\n<p><strong>\u00bb\u00a0<\/strong><a href=\"https:\/\/www.pcb.ub.edu\/es\/onechain-recibe-el-premio-joan-roget-al-mejor-caso-de-exito-de-transferencia-de-conocimiento\/\" target=\"_blank\" rel=\"noopener\"><strong>Noticia relacionada [+]<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La empresa biotecnol\u00f3gica en fase cl\u00ednica OneChain Immunotherapeutics (OCI), ubicada en el Parque Cient\u00edfico de Barcelona y centrada en el desarrollo de terapias CAR T para el tratamiento de enfermedades&#8230;<\/p>\n","protected":false},"author":4,"featured_media":92386,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[356],"tags":[],"class_list":["post-92405","post","type-post","status-publish","format-standard","has-post-thumbnail","category-empresas"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"La empresa biotecnol\u00f3gica en fase cl\u00ednica OneChain Immunotherapeutics (OCI), ubicada en el Parque Cient\u00edfico de Barcelona y centrada en el desarrollo de terapias CAR T para el tratamiento de enfermedades...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-01T10:24:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T13:12:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/Stefanos_Theoharis_OCI-003.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Azucena Berea\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Azucena Berea\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/\"},\"author\":{\"name\":\"Azucena Berea\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\"},\"headline\":\"Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics\",\"datePublished\":\"2024-02-01T10:24:45+00:00\",\"dateModified\":\"2025-10-13T13:12:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/\"},\"wordCount\":694,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Stefanos_Theoharis_OCI-003.png\",\"articleSection\":[\"EMPRESAS\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/\",\"name\":\"Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Stefanos_Theoharis_OCI-003.png\",\"datePublished\":\"2024-02-01T10:24:45+00:00\",\"dateModified\":\"2025-10-13T13:12:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Stefanos_Theoharis_OCI-003.png\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/Stefanos_Theoharis_OCI-003.png\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\",\"name\":\"Azucena Berea\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"caption\":\"Azucena Berea\"},\"sameAs\":[\"https:\\\/\\\/www.pcb.ub.edu\"],\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/aberea\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/","og_locale":"es_ES","og_type":"article","og_title":"Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics - Parc Cient\u00edfic de Barcelona","og_description":"La empresa biotecnol\u00f3gica en fase cl\u00ednica OneChain Immunotherapeutics (OCI), ubicada en el Parque Cient\u00edfico de Barcelona y centrada en el desarrollo de terapias CAR T para el tratamiento de enfermedades...","og_url":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2024-02-01T10:24:45+00:00","article_modified_time":"2025-10-13T13:12:06+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/Stefanos_Theoharis_OCI-003.png","type":"image\/png"}],"author":"Azucena Berea","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Azucena Berea","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/"},"author":{"name":"Azucena Berea","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239"},"headline":"Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics","datePublished":"2024-02-01T10:24:45+00:00","dateModified":"2025-10-13T13:12:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/"},"wordCount":694,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/Stefanos_Theoharis_OCI-003.png","articleSection":["EMPRESAS"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/","url":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/","name":"Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/Stefanos_Theoharis_OCI-003.png","datePublished":"2024-02-01T10:24:45+00:00","dateModified":"2025-10-13T13:12:06+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/Stefanos_Theoharis_OCI-003.png","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/02\/Stefanos_Theoharis_OCI-003.png","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/stefanos-theoharis-nuevo-ceo-de-onechain-immunotherapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Stefanos Theoharis, nuevo CEO de OneChain Immunotherapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239","name":"Azucena Berea","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","caption":"Azucena Berea"},"sameAs":["https:\/\/www.pcb.ub.edu"],"url":"https:\/\/www.pcb.ub.edu\/es\/author\/aberea\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/92405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=92405"}],"version-history":[{"count":6,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/92405\/revisions"}],"predecessor-version":[{"id":93466,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/92405\/revisions\/93466"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/92386"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=92405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=92405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=92405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}